Hiểu biết hiện tại về chẩn đoán và điều trị bệnh Alzheimer

M Crous-Bou, 2017, Alzheimer's disease prevention: from risk factors to early intervention., Alzheimers Res Ther., 9, 71, 10.1186/s13195-017-0297-z

2017, 2017 Alzheimer's disease facts and figures., Alzheimers Dement., 13, 325-73, 10.1016/j.jalz.2017.02.001

C Takizawa, 2015, Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America., J Alzheimers Dis., 43, 1271-84, 10.3233/JAD-141134

A Budson, 2012, New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician., Neurologist., 18, 356-63, 10.1097/NRL.0b013e31826a998d

E Mossello, 2012, Management of patients with Alzheimer's disease: pharmacological treatment and quality of life., Ther Adv Chronic Dis., 3, 183-93, 10.1177/2040622312452387

G McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement., 7, 263-9, 10.1016/j.jalz.2011.03.005

M Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement., 7, 270-9, 10.1016/j.jalz.2011.03.008

R Sperling, 2011, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement., 7, 280-92, 10.1016/j.jalz.2011.03.003

2013, Diagnostic and Statistical Manual of Mental Disorders

C Clark, 2012, Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study., Lancet Neurol., 11, 669-78, 10.1016/S1474-4422(12)70142-4

L Saint-Aubert, 2013, Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients., EJNMMI Res., 3, 43, 10.1186/2191-219X-3-43

J Yeo, 2015, A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer's disease., Alzheimers Dement (Amst)., 1, 5-13, 10.1016/j.dadm.2014.11.004

O Sabri, 2015, Beta-amyloid imaging with florbetaben., Clin Transl Imaging., 3, 13-26, 10.1007/s40336-015-0102-6

H Hampel, 2008, Core candidate neurochemical and imaging biomarkers of Alzheimer's disease., Alzheimers Dement., 4, 38-48, 10.1016/j.jalz.2007.08.006

S Palmqvist, 2015, Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease., Neurology., 85, 1240-9, 10.1212/WNL.0000000000001991

Y Shen, 2018, Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment., Biol Psychiatry., 83, 447-55, 10.1016/j.biopsych.2017.02.007

H Dong, 2015, Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer's Disease., Dis Markers., 2015, 10.1155/2015/625659

B Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis., Lancet Neurol., 15, 673-84, 10.1016/S1474-4422(16)00070-3

R Howard, 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease., N Engl J Med., 366, 893-903, 10.1056/NEJMoa1106668

G Grossberg, 2013, The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors., CNS Drugs., 27, 469-78, 10.1007/s40263-013-0077-7

S Xing, 2014, Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis., Evid Based Complement Alternat Med., 2014, 10.1155/2014/363985

T Littlejohns, 2014, Vitamin D and the risk of dementia and Alzheimer disease., Neurology., 83, 920-8, 10.1212/WNL.0000000000000755

P Gupta, 2015, Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials., Am J Alzheimers Dis Other Demen., 30, 178-82, 10.1177/1533317514542644

L Lee, 2013, Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial., Psychopharmacology (Berl)., 225, 605-12, 10.1007/s00213-012-2848-0

Y Bo, 2017, The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial., Nutrients., 9, 10.3390/nu9010054

P Gorelick, 2017, Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association., Stroke., 48, e284-e303, 10.1161/STR.0000000000000148

I Lourida, 2013, Mediterranean diet, cognitive function, and dementia: a systematic review., Epidemiology., 24, 479-89, 10.1097/EDE.0b013e3182944410

B Singh, 2014, Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis., J Alzheimers Dis., 39, 271-82, 10.3233/JAD-130830

F Stella, 2011, Attenuation of neuropsychiatric symptoms and caregiver burden in Alzheimer's disease by motor intervention: a controlled trial., Clinics (Sao Paulo)., 66, 1353-60, 10.1590/S1807-59322011000800008

A Dregan, 2013, Leisure-time physical activity over the life course and cognitive functioning in late mid-adult years: a cohort-based investigation., Psychol Med., 43, 2447-58, 10.1017/S0033291713000305

J Smith, 2014, Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease., Front Aging Neurosci., 6, 61, 10.3389/fnagi.2014.00061

D Mann, 2013, Amyloid or tau: the chicken or the egg?, Acta Neuropathol., 126, 609-13, 10.1007/s00401-013-1162-1

H Braak, 2013, Reply: the early pathological process in sporadic Alzheimer's disease., Acta Neuropathol., 126, 615-8, 10.1007/s00401-013-1170-1

K Kosik, 2013, Diseases: Study neuron networks to tackle Alzheimer's., Nature., 503, 31-2, 10.1038/503031a

P Aisen, 2017, EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials., J Prev Alzheimers Dis., 4, 116-24, 10.14283/jpad.2017.13

R Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer's disease., N Engl J Med., 367, 795-804, 10.1056/NEJMoa1202753

A Pooler, 2013, Propagation of tau pathology in Alzheimer's disease: identification of novel therapeutic targets., Alzheimers Res Ther., 5, 49, 10.1186/alzrt214

S Salloway, 2014, Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease., N Engl J Med., 370, 322-33, 10.1056/NEJMoa1304839

R Doody, 2014, Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med., 370, 311-21, 10.1056/NEJMoa1312889

L Honig, 2018, Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease., N Engl J Med., 378, 321-30, 10.1056/NEJMoa1705971

R Vassar, 2014, BACE1 inhibitor drugs in clinical trials for Alzheimer's disease., Alzheimers Res Ther., 6, 89, 10.1186/s13195-014-0089-7

M Kennedy, 2016, The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients., Sci Transl Med., 8, 363ra150, 10.1126/scitranslmed.aad9704

H Jacobsen, 2014, Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice., J Neurosci., 34, 11621-30, 10.1523/JNEUROSCI.1405-14.2014

D Perry, 2015, Building a roadmap for developing combination therapies for Alzheimer's disease., Expert Rev Neurother., 15, 327-33, 10.1586/14737175.2015.996551

J Pedersen, 2015, Tau immunotherapy for Alzheimer's disease., Trends Mol Med., 21, 394-402, 10.1016/j.molmed.2015.03.003

H Rosenmann, 2013, Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies., Curr Alzheimer Res., 10, 217-28, 10.2174/1567205011310030001

P Novak, 2017, Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial., Lancet Neurol., 16, 123-34, 10.1016/S1474-4422(16)30331-3

F Panza, 2016, Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy., Immunotherapy., 8, 1119-34, 10.2217/imt-2016-0019

R Canter, 2016, The road to restoring neural circuits for the treatment of Alzheimer's disease., Nature., 539, 187-96, 10.1038/nature20412

G Buzsáki, 2012, Mechanisms of gamma oscillations., Annu Rev Neurosci., 35, 203-25, 10.1146/annurev-neuro-062111-150444

P Sederberg, 2007, Gamma oscillations distinguish true from false memories., Psychol Sci., 18, 927-32, 10.1111/j.1467-9280.2007.02003.x

H Iaccarino, 2016, Gamma frequency entrainment attenuates amyloid load and modifies microglia., Nature., 540, 230-5, 10.1038/nature20587